INZYUnknownMicro-Cap
Inozyme Pharma, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Inozyme Pharma, Inc. (INZY), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are INZY insiders buying or selling?
Inozyme Pharma, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since July 2020, Trabud has recorded 31 Form 4 filings for INZY: 27 buys ($104.1M) and 4 sells ($7.9M).
Source: SEC EDGAR Form 4
Key Statistics (July 2020 – Apr 3, 2025)
Total Form 4 filings
31
SEC EDGAR
Insider filers
19
Insider buys (27)
$104.1M
Insider sells (4)
$7.9M
Insider sentiment
Net buyingNet insider flow of $96.2M in net buying since July 2020.
Recent INZY insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Apr 3, 2025 | Douglas A Treco | CEO & Chairman | Sale | 8.8K | $0.89 | $7.8K | SEC ↗ |
| Apr 3, 2024 | Douglas A Treco | CEO | Sale | 7.5K | $6.94 | $52.2K | SEC ↗ |
| Aug 4, 2023 | Pivotal bioVenture Partners Fund I, L.P. | Director | Purchase | 833.3K | $4.80 | $4.0M | SEC ↗ |
| Aug 4, 2023 | Robert Lorne Hopfner | Director | Purchase | 833.3K | $4.80 | $4.0M | SEC ↗ |
| May 15, 2023 | Robert Lorne Hopfner | Director | Purchase | 447.9K | $6.36 | $2.8M | SEC ↗ |
| Mar 30, 2023 | Robert Lorne Hopfner | Director | Purchase | 344.6K | $4.54 | $1.6M | SEC ↗ |
| Mar 29, 2023 | Robert Lorne Hopfner | Director | Purchase | 207.8K | $4.05 | $841.1K | SEC ↗ |
| Dec 19, 2022 | Henric Bjorn Bjarke | SVP, COO | Purchase | 21.5K | $1.39 | $29.9K | SEC ↗ |
| Apr 21, 2022 | Bakker Juliet Tammenoms | 10% Owner | Purchase | 1.4M | $3.69 | $5.0M | SEC ↗ |
| Apr 20, 2022 | Pivotal bioVenture Partners Fund I, L.P. | Director | Purchase | 1.1M | $3.69 | $3.9M | SEC ↗ |
| Apr 20, 2022 | Henric Bjorn Bjarke | SVP, COO | Purchase | 27.1K | $3.69 | $100.0K | SEC ↗ |
| Apr 20, 2022 | Axel Bolte | Chief Executive Officer | Purchase | 67.8K | $3.69 | $250.0K | SEC ↗ |
| Apr 20, 2022 | Robert Lorne Hopfner | Director | Purchase | 1.1M | $3.69 | $3.9M | SEC ↗ |
| Apr 20, 2022 | Sanjay Subramanian | SVP, CFO | Purchase | 27.1K | $3.69 | $100.0K | SEC ↗ |
| Jun 25, 2021 | Axel Bolte | Chief Executive Officer | Sale | 66.8K | $0.00 | $6.68 | SEC ↗ |
| Feb 1, 2021 | Novo Holdings A/S | 10% Owner | Sale | 375.0K | $21.00 | $7.9M | SEC ↗ |
| Jul 29, 2020 | Novo Holdings A/S | 10% Owner | Purchase | 375.0K | $16.00 | $6.0M | SEC ↗ |
| Jul 29, 2020 | Sanofi | 10% Owner | Purchase | 81.3K | $16.00 | $1.3M | SEC ↗ |
| Jul 29, 2020 | Rock Springs Capital Management LP | 10% Owner | Purchase | 600.0K | $16.00 | $9.6M | SEC ↗ |
| Jul 28, 2020 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Purchase | 600.0K | $16.00 | $9.6M | SEC ↗ |
| Jul 28, 2020 | Peter W. Sonsini | 10% Owner | Purchase | 250.0K | $16.00 | $4.0M | SEC ↗ |
| Jul 28, 2020 | Scott D Sandell | 10% Owner | Purchase | 250.0K | $16.00 | $4.0M | SEC ↗ |
| Jul 28, 2020 | Joshua Makower | 10% Owner | Purchase | 250.0K | $16.00 | $4.0M | SEC ↗ |
| Jul 28, 2020 | Mohamad Makhzoumi | 10% Owner | Purchase | 250.0K | $16.00 | $4.0M | SEC ↗ |
| Jul 28, 2020 | Anthony A. Florence Jr. | 10% Owner | Purchase | 250.0K | $16.00 | $4.0M | SEC ↗ |
Showing the 25 most recent of 31 Form 4 filings for Inozyme Pharma, Inc..
Most active INZY insiders
- Robert Lorne Hopfner6 filings
- Pivotal bioVenture Partners Fund I, L.P.3 filings
- Axel Bolte2 filings
- Douglas A Treco2 filings
- Henric Bjorn Bjarke2 filings
Ask anything about INZY insider activity
Use Trabud's AI agent to query Inozyme Pharma, Inc.'s Form 4 history in plain English — "Show me INZY CEO purchases this year" or compare it against any other ticker.
Open the AI agentINZY insider trading FAQ
Are Inozyme Pharma, Inc. insiders buying or selling?
Inozyme Pharma, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since July 2020, Trabud has recorded 31 Form 4 filings for INZY: 27 buys ($104.1M) and 4 sells ($7.9M). Over the full record that is net buying of $96.2M.
How many insiders trade INZY stock?
19 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Inozyme Pharma, Inc.. The most recent filing was accepted on Apr 3, 2025.
Where does Trabud get INZY insider trading data?
All INZY insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.